REGENERON PHARMACEUTICALS, INC. Quarterly Operating Income (Loss) in USD from Q1 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Regeneron Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2010 to Q2 2024.
  • Regeneron Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was $1.07B, a 5.22% increase year-over-year.
  • Regeneron Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was $3.9B, a 9.9% decline year-over-year.
  • Regeneron Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was $4.05B, a 14.6% decline from 2022.
  • Regeneron Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was $4.74B, a 47% decline from 2021.
  • Regeneron Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was $8.95B, a 150% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $3.9B $1.07B +$53.1M +5.22% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $3.85B $751M -$195M -20.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $4.05B $973M -$174M -15.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-05
Q3 2023 $4.22B $1.11B -$113M -9.21% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 $4.33B $1.02B -$93.4M -8.42% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $4.43B $947M -$312M -24.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $4.74B $1.15B -$1.49B -56.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-05
Q3 2022 $6.23B $1.22B -$624M -33.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $6.86B $1.11B -$2.24B -66.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $9.09B $1.26B +$146M +13.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $8.95B $2.64B +$1.47B +126% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-05
Q3 2021 $7.47B $1.85B +$794M +75.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $6.68B $3.35B +$2.69B +410% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $3.99B $1.11B +$413M +58.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $3.58B $1.17B +$491M +72.7% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-06
Q3 2020 $3.09B $1.05B +$315M +42.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $2.77B $656M +$341M +108% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $2.43B $700M +$220M +45.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $2.21B $676M -$42.4M -5.9% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-07
Q3 2019 $2.25B $739M +$112M +17.8% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $2.14B $316M -$307M -49.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $2.45B $480M -$87.2M -15.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q4 2018 $2.53B $718M +$179M +33.3% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-08
Q3 2018 $2.36B $627M +$67M +12% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 $2.29B $622M +$71.9M +13.1% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $2.22B $567M +$137M +31.7% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q4 2017 $2.08B $539M +$192M +55.3% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-07
Q3 2017 $1.89B $560M +$197M +54.3% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 $1.69B $550M +$259M +88.7% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $1.43B $431M +$101M +30.7% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-03
Q4 2016 $1.33B $347M +$116M +50.1% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-07
Q3 2016 $1.21B $363M -$29.6M -7.55% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q2 2016 $1.24B $292M -$53.2M -15.4% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-03
Q1 2016 $1.3B $329M +$45.8M +16.1% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-04
Q4 2015 $1.25B $231M +$15.3M +7.08% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-08
Q3 2015 $1.24B $392M +$204M +108% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-04
Q2 2015 $1.03B $345M +$117M +51.2% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-04
Q1 2015 $916M $284M +$92M +48% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-05
Q4 2014 $824M $216M +$20.7M +10.6% Oct 1, 2014 Dec 31, 2014 10-Q 2015-11-04
Q3 2014 $803M $188M -$48.3M -20.4% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-04
Q2 2014 $852M $228M +$70M +44.3% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-04
Q1 2014 $782M $192M +$38.5M +25.2% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-07
Q4 2013 $743M $195M +$49.4M +33.9% Oct 1, 2013 Dec 31, 2013 10-K 2016-02-11
Q3 2013 $694M $237M +$34.4M +17% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-04
Q2 2013 $659M $158M +$70.6M +80.7% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-05
Q1 2013 $589M $153M +$131M +589% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-08
Q4 2012 $458M $146M +$191M Oct 1, 2012 Dec 31, 2012 10-K 2015-02-12
Q3 2012 $267M $202M +$261M Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-05
Q2 2012 $5.82M $87.5M +$148M Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-06
Q1 2012 -$142M $22.2M +$63.2M Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-03
Q4 2011 -$205M -$45.4M -$32.6M -255% Oct 1, 2011 Dec 31, 2011 10-K 2014-02-13
Q3 2011 -$173M -$58.5M -$26.4M -82.1% Jul 1, 2011 Sep 30, 2011 10-Q 2012-10-24
Q2 2011 -$146M -$60.3M -$36.6M -154% Apr 1, 2011 Jun 30, 2011 10-Q 2012-07-25
Q1 2011 -$110M -$41M -$12.1M -41.9% Jan 1, 2011 Mar 31, 2011 10-Q 2012-04-26
Q4 2010 -$97.5M -$12.8M Oct 1, 2010 Dec 31, 2010 10-K 2013-02-15
Q3 2010 -$32.1M Jul 1, 2010 Sep 30, 2010 10-Q 2011-10-27
Q2 2010 -$23.7M Apr 1, 2010 Jun 30, 2010 10-Q 2011-07-28
Q1 2010 -$28.9M Jan 1, 2010 Mar 31, 2010 10-Q 2011-05-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.